RU2015152860A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2015152860A3 RU2015152860A3 RU2015152860A RU2015152860A RU2015152860A3 RU 2015152860 A3 RU2015152860 A3 RU 2015152860A3 RU 2015152860 A RU2015152860 A RU 2015152860A RU 2015152860 A RU2015152860 A RU 2015152860A RU 2015152860 A3 RU2015152860 A3 RU 2015152860A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1310698.4 | 2013-06-14 | ||
| GB201310698A GB201310698D0 (en) | 2013-06-14 | 2013-06-14 | Method |
| GB1405140.3 | 2014-03-22 | ||
| GB201405140A GB201405140D0 (en) | 2014-03-22 | 2014-03-22 | Method |
| GB1406509.8 | 2014-04-10 | ||
| GB201406509A GB201406509D0 (en) | 2014-04-10 | 2014-04-10 | Method |
| PCT/EP2014/062284 WO2014198852A2 (en) | 2013-06-14 | 2014-06-12 | A dosing regime and formulations for type b adenoviruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2015152860A RU2015152860A (ru) | 2017-07-19 |
| RU2015152860A3 true RU2015152860A3 (OSRAM) | 2018-05-04 |
| RU2671558C2 RU2671558C2 (ru) | 2018-11-02 |
Family
ID=51162703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015152860A RU2671558C2 (ru) | 2013-06-14 | 2014-06-12 | Режим введения и составы для аденовирусов типа в |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11173186B2 (OSRAM) |
| EP (2) | EP3007711B1 (OSRAM) |
| JP (2) | JP6797680B2 (OSRAM) |
| KR (3) | KR20210054067A (OSRAM) |
| CN (2) | CN105431157A (OSRAM) |
| AU (2) | AU2014280123B2 (OSRAM) |
| BR (1) | BR112015030881A2 (OSRAM) |
| CA (2) | CA3176971A1 (OSRAM) |
| IL (1) | IL243071B (OSRAM) |
| RU (1) | RU2671558C2 (OSRAM) |
| SG (1) | SG11201510064WA (OSRAM) |
| WO (1) | WO2014198852A2 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| JP7114571B2 (ja) * | 2017-03-31 | 2022-08-08 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
| GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| CN111989397A (zh) * | 2018-03-30 | 2020-11-24 | 藤堂具纪 | 肿胀发生抑制型溶瘤病毒 |
| CA3156171A1 (en) * | 2019-09-30 | 2021-04-08 | Candel Therapeutics, Inc. | CANCER TREATMENT BY COMBINED GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY AND ATR INHIBITOR |
| CN114469938A (zh) * | 2020-10-27 | 2022-05-13 | 中国医学科学院药物研究所 | 化合物bix02189在制备抗流感病毒药物中的应用 |
| CN114601838B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种azd8055在制备用于抗腺病毒感染的药物中的用途 |
| WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
| WO2024243578A1 (en) | 2023-05-25 | 2024-11-28 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| CA2305269C (en) | 1997-10-09 | 2012-07-03 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| JP4409097B2 (ja) | 1998-12-09 | 2010-02-03 | アメリカ合衆国 | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
| CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| IL145447A0 (en) | 1999-04-09 | 2002-06-30 | Aventis Pharma Sa | Composition for the preservation of infectious recombinant adenoviruses |
| GB9913359D0 (en) | 1999-06-09 | 1999-08-11 | Cancer Res Campaign Tech | Polymer modified biological elements |
| ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| US20040167088A1 (en) * | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| AU2004260044B2 (en) * | 2003-07-18 | 2009-04-23 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
| EP2292664B1 (en) | 2003-10-16 | 2016-11-23 | Amgen Research (Munich) GmbH | Multispecific deimmunized CD3-binders |
| JP2007522814A (ja) | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | ウイルスの精製方法 |
| CN102816742B (zh) * | 2004-05-26 | 2014-04-09 | 普西奥克瑟斯医疗有限公司 | 用于治疗癌症的嵌合腺病毒 |
| GB0416487D0 (en) | 2004-07-23 | 2004-08-25 | Isis Innovation | Modified virus |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| RU2382884C2 (ru) | 2006-07-10 | 2010-02-27 | Александр Владимирович Дидин | Сферическая объемная роторная машина и способ работы сферической объемной роторной машины |
| EP2094284A2 (en) * | 2006-12-22 | 2009-09-02 | Bayer Schering Pharma AG | Generation of oncolytic adenoviruses and uses thereof |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| MX339014B (es) | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| PE20110598A1 (es) | 2008-10-02 | 2011-08-31 | Respivert Ltd | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| CN102245215A (zh) | 2008-12-11 | 2011-11-16 | 普西奥库斯治疗有限公司 | 用包含带电荷的季氨基的聚合物的核酸载体的修饰 |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| NO2748201T3 (OSRAM) | 2011-08-23 | 2018-05-12 | ||
| JP2015507604A (ja) | 2011-11-14 | 2015-03-12 | リジェネレイティブ サイエンシーズ， エルエルシー | 懸濁粒子送達システムおよび方法 |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| EP3831398A1 (en) | 2013-10-25 | 2021-06-09 | PsiOxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
| HUE042829T2 (hu) | 2014-04-03 | 2019-07-29 | Igm Biosciences Inc | Módosított J-lánc |
| JP2017529070A (ja) | 2014-08-27 | 2017-10-05 | サイオクサス セラピューティクス リミテッド | アデノウイルスの製造方法 |
| US11000559B2 (en) | 2015-04-30 | 2021-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein |
-
2014
- 2014-06-12 KR KR1020217013679A patent/KR20210054067A/ko not_active Ceased
- 2014-06-12 WO PCT/EP2014/062284 patent/WO2014198852A2/en not_active Ceased
- 2014-06-12 SG SG11201510064WA patent/SG11201510064WA/en unknown
- 2014-06-12 EP EP14736650.4A patent/EP3007711B1/en not_active Revoked
- 2014-06-12 BR BR112015030881A patent/BR112015030881A2/pt not_active Application Discontinuation
- 2014-06-12 KR KR1020167000214A patent/KR20160026970A/ko not_active Ceased
- 2014-06-12 KR KR1020217041147A patent/KR20210156857A/ko not_active Ceased
- 2014-06-12 CN CN201480033427.XA patent/CN105431157A/zh active Pending
- 2014-06-12 US US14/896,294 patent/US11173186B2/en active Active
- 2014-06-12 CA CA3176971A patent/CA3176971A1/en active Pending
- 2014-06-12 RU RU2015152860A patent/RU2671558C2/ru active
- 2014-06-12 CA CA2914790A patent/CA2914790C/en active Active
- 2014-06-12 AU AU2014280123A patent/AU2014280123B2/en active Active
- 2014-06-12 EP EP20198714.6A patent/EP3777870A1/en active Pending
- 2014-06-12 JP JP2016518498A patent/JP6797680B2/ja active Active
- 2014-06-12 CN CN202011432713.7A patent/CN112516179A/zh active Pending
-
2015
- 2015-12-09 IL IL24307115A patent/IL243071B/en active IP Right Revival
-
2020
- 2020-02-14 AU AU2020201101A patent/AU2020201101B2/en active Active
- 2020-09-09 JP JP2020151615A patent/JP2020203932A/ja active Pending
-
2021
- 2021-09-23 US US17/448,549 patent/US12350302B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2914790A1 (en) | 2014-12-18 |
| CA3176971A1 (en) | 2014-12-18 |
| HK1223564A1 (zh) | 2017-08-04 |
| AU2020201101B2 (en) | 2021-10-21 |
| US20220054563A1 (en) | 2022-02-24 |
| AU2014280123B2 (en) | 2019-11-14 |
| CN112516179A (zh) | 2021-03-19 |
| RU2671558C2 (ru) | 2018-11-02 |
| CN105431157A (zh) | 2016-03-23 |
| JP2016526531A (ja) | 2016-09-05 |
| AU2020201101A1 (en) | 2020-03-05 |
| JP2020203932A (ja) | 2020-12-24 |
| US12350302B2 (en) | 2025-07-08 |
| WO2014198852A3 (en) | 2015-04-02 |
| KR20160026970A (ko) | 2016-03-09 |
| WO2014198852A2 (en) | 2014-12-18 |
| RU2015152860A (ru) | 2017-07-19 |
| SG11201510064WA (en) | 2016-01-28 |
| US20160120922A1 (en) | 2016-05-05 |
| EP3007711A2 (en) | 2016-04-20 |
| CA2914790C (en) | 2024-02-27 |
| JP6797680B2 (ja) | 2020-12-16 |
| EP3007711B1 (en) | 2020-10-21 |
| IL243071B (en) | 2019-10-31 |
| EP3777870A1 (en) | 2021-02-17 |
| BR112015030881A2 (pt) | 2017-10-24 |
| KR20210054067A (ko) | 2021-05-12 |
| US11173186B2 (en) | 2021-11-16 |
| KR20210156857A (ko) | 2021-12-27 |
| AU2014280123A1 (en) | 2016-01-28 |